---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000113"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:17:03.908848+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics Q2 net loss $60.4M; ivonescimab achieves first Phase III win over Keytruda

## Summary
- GAAP net loss $60.4M ($0.09/sh) vs $14.7M ($0.02) in Q2 2023; non-GAAP loss $34.3M.
- Cash $325.8M (up from $186.2M) after $200M June equity offering; runway into Q4 2025.
- HARMONi-2: ivonescimab monotherapy beat pembrolizumab in 1L NSCLC, first drug to do so in Phase III.
- HARMONi-A: ivonescimab+chemo reduced progression/death by 54% (HR 0.46) in EGFR-mutated NSCLC post-TKI.
- Expanded license to Latin America, Middle East, Africa; five-year strategic collaboration with MD Anderson.

## SEC filing metadata
- accession: 0001599298-24-000113
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000113/0001599298-24-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000113/smmt-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000113
- JSON: https://secwatch.observer/filing/0001599298-24-000113.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.